))
A Cry for Help? FDA Bares Concerns in NEJM
Archived series ("Inactive feed" status)
When?
This feed was archived on June 24, 2019 01:42 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 178903522 series 69146
Content provided by RRY Publications and LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by RRY Publications and LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The most senior FDA executives went public with their worries, frustration even, we suspect, impotence regarding the plethora of stem cells therapies in the market last November. And that article, which appeared in the New England Journal of Medicine just keeps growing in influence. Here is what Celia Whitten, Peter Marks and Robert Califf said.
100 episodes
Share
